['polycystic ovary syndrome', 'disorder of glucose regulation']
['metformin xr', 'saxagliptin', 'saxagliptin-metformin xr']

        Inclusion Criteria:

          -  Females 18 years to 42 years of age with polycystic ovary syndrome(NIH PCOS criteria)
             with prediabetic hyperglycemia determined by an 75 gram oral glucose tolerance test
             (OGTT). Study subjects will be inclusive of PCOS women with impaired fasting glucose
             (IFG), impaired glucose tolerance (IGT), or both (IFG/IGT).

          -  Written consent for participation in the study

        Exclusion Criteria:

          -  Presence of significant systemic disease, heart problems including congestive heart
             failure, history of pancreatitis, or diabetes mellitus (Type 1 or 2)

          -  Any hepatic diseases in the past (viral hepatitis, toxic hepatic damage, jaundice of
             unknown etiology), gallstones, abnormal liver function tests or renal impairment
             (elevated serum creatinine levels or abnormal creatinine clearance)

          -  Uncontrolled thyroid disease (documented normal TSH), Cushing's syndrome, congenital
             adrenal hyperplasia or hyperprolactinemia

          -  Significantly elevated triglyceride levels (fasting triglyceride > 400 mg %)

          -  Untreated or poorly controlled hypertension (sitting blood pressure > 160/95 mm Hg)

          -  Use of hormonal medications, drugs known to affect gastrointestinal motility,
             lipid-lowering (statins, etc.) and/or anti-obesity drugs or medications that interfere
             with carbohydrate metabolism (such as isotretinoin, hormonal contraceptives,
             gonadotropin releasing hormone (GnRH) analogues, glucocorticoids, anabolic steroids,
             C-19 progestins) for at least 8 weeks. Use of anti-androgens that act peripherally to
             reduce hirsutism such as 5-alpha reductase inhibitors (finasteride, spironolactone,
             flutamide) for at least 4 weeks

          -  Prior history of a malignant disease requiring chemotherapy

          -  Known hypersensitivity or contraindications to use of insulin sensitizers such as
             metformin or thiazolidinediones

          -  History of hypersensitivity reaction to saxagliptin or other DPP-4 inhibitors (e.g.
             anaphylaxis, angioedema, exfoliative skin conditions)

          -  Current use of metformin, thiazolidinediones, glucagon-like peptide -1 receptor
             agonists, DPP-4 inhibitors, or weight loss medications (prescription or OTC) Patients
             must stop use of insulin sensitizers or antidiabetic medicines such as metformin for
             at least 4 weeks or thiazolidinediones, GLP1 agonists or DPPIV inhibitors for 8 weeks.

          -  Prior use of medication to treat diabetes except gestational diabetes

          -  Use of drugs known to exacerbate glucose tolerance

          -  Eating disorders (anorexia, bulimia) or gastrointestinal disorders

          -  Suspected pregnancy (documented negative serum pregnancy test), desiring pregnancy
             during the study treatment interval, breastfeeding, or known pregnancy in last 2
             months

          -  Active or prior history of substance abuse (smoke or tobacco use within past 3 years)
             or significant intake of alcohol or history of alcoholism

          -  Patient not willing to use adequate barrier contraception during study period (unless
             sterilized or have an IUD).

          -  Debilitating psychiatric disorder such as psychosis or neurological condition that
             might confound outcome variables

          -  Inability or refusal to comply with protocol

          -  Not currently participating or having participated in an experimental drug study in
             previous three months
      